Pharmacokinetics (PK) of Trastuzumab Emtansine and Paclitaxel or Docetaxel in Patients with HER2-Positive MBC Previously Treated with a Trastuzumab-Containing Regimen.

被引：1
|
作者：
Lu, D. [1 ]
Modi, S. [1 ]
Elias, A. D. [1 ]
Agarwal, P. [1 ]
Yi, J-H [1 ]
Guardino, A. E. [1 ]
Althaus, B. L. [1 ]
Girish, S. [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P1-12-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-12-07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics (PK) of Trastuzumab-DM1 (T-DM1) and Paclitaxel (T) in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen
    Lu, D.
    Krop, I.
    Modi, S.
    Elias, A.
    LoRusso, P.
    Huang, J.
    Lu, M.
    Girish, S.
    CANCER RESEARCH, 2010, 70
  • [2] Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Chen, Shang-Chiung
    Kagedal, Matts
    Gao, Yuying
    Wang, Bei
    Harle-Yge, Marie-Laurence
    Girish, Sandhya
    Jin, Jin
    Li, Chunze
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1147 - 1159
  • [3] Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Shang-Chiung Chen
    Matts Kagedal
    Yuying Gao
    Bei Wang
    Marie-Laurence Harle-Yge
    Sandhya Girish
    Jin Jin
    Chunze Li
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1147 - 1159
  • [4] Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Shang-Chiung Chen
    Matts Kagedal
    Yuying Gao
    Bei Wang
    Marie-Laurence Harle-Yge
    Sandhya Girish
    Jin Jin
    Chunze Li
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 421 - 422
  • [5] Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
    Chunze Li
    Bei Wang
    Shang-Chiung Chen
    Russell Wada
    Dan Lu
    Xin Wang
    Daniel Polhamus
    Jonathan French
    Shweta Vadhavkar
    Alexander Strasak
    Melanie Smitt
    Amita Joshi
    Meghna Samant
    Angelica Quartino
    Jin Jin
    Sandhya Girish
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1079 - 1090
  • [6] Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
    Li, Chunze
    Wang, Bei
    Chen, Shang-Chiung
    Wada, Russell
    Lu, Dan
    Wang, Xin
    Polhamus, Daniel
    French, Jonathan
    Vadhavkar, Shweta
    Strasak, Alexander
    Smitt, Melanie
    Joshi, Amita
    Samant, Meghna
    Quartino, Angelica
    Jin, Jin
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1079 - 1090
  • [7] A Dose-Escalation Study of Trastuzumab-DM1 (T-DM1), Paclitaxel (T), and Pertuzumab (P) in Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen
    Krop, I. E.
    Modi, S.
    Elias, A.
    LoRusso, P.
    Choi, Y. J.
    Lu, M.
    CANCER RESEARCH, 2010, 70
  • [8] Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen.
    Sail, K.
    Lalla, D.
    Brammer, M.
    Halm, M.
    Patt, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
    Dhillon, Sohita
    DRUGS, 2014, 74 (06) : 675 - 686
  • [10] Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
    Sohita Dhillon
    Drugs, 2014, 74 : 675 - 686
12345